Jane E. Henney, MD, senior vice president and provost for health affairs at UC, was appointed to the Board of Trustees of Omeris—a non-profit organization designed to accelerate and promote bioscience commercialization, research and education in Ohio.
In addition to Dr. Henney, Mike Hooven, chairman and CTO of AtriCure, a Cincinnati-based company focused on the development of products and procedures to treat atrial fibrillation, has also been named to the Omeris board.
UC’s Academic Health Center is a leader in forming partnerships with industry and academic institutions to enhance our research efforts, improve upon our patient care and provide world-class education,” says Dr. Henney. “I am pleased to join this ‘force’ of academic and business leaders to enhance Ohio’s position as a biotechnology leader.”
Omeris also announced the election of David Scholl, PhD, to chairman of the board. He is president and CEO of Diagnostic Hybrids in Athens, Ohio, which develops and manufactures diagnostic cell cultures and virus detection kit systems used in the clinical diagnosis of infectious and autoimmune diseases. Dr. Scholl has been an Omeris board member since 2002.
The Omeris Board of Trustees also includes: John Bantle, II, PhD, Ohio University; Timothy Biro, Ohio Innovation Fund; Mark Collar, Procter & Gamble Pharmaceuticals; Tony Dennis, PhD, Omeris; Joseph Hahn, MD, The Cleveland Clinic Foundation; Peter Kleinhenz, CID Equity Partners; John Rice, PhD, Triathlon Medical Ventures; Richard Rosen, Battelle; Fred Sanfilippo, MD, PhD, The Ohio State University; Bill Sanford, SYMARK; Jim Scozzie, PhD, BioEnterprise; and Donald Wetherhold, RxPedite.
Omeris is supported by the Thomas Edison Program of the Ohio Department of Development. For more information, visit www.omeris.org.